Cooper Companies (COO) Bets on Fertility Growth Despite Weakness in CooperVision
Cooper Companies (COO) reported Q3 FY2026 revenue of $1.066B, up 1%, and adjusted EPS of $1.15, up 4%. The company spent $339.1M on share buybacks and has $1.5B remaining in repurchase capacity. Fertility segment growth and strong cash flow offset weakness in CooperVision, which saw flat organic growth and revenue declines in Americas and Asia Pacific. Gross margin improved to 67% on a GAAP basis, while adjusted operating margin rose 30 basis points to 26%.
How this was made
The 30-second read
Why it matters
Earnings beat and buyback suggest near‑term buying interest, but segment weakness tempers upside.
Market read
Earnings release provides fresh data for traders; the buyback adds a catalyst for short‑term price moves.
What to watch
Currency headwinds and higher manufacturing costs may limit margin expansion.
Background
Cooper Companies reported Q3 FY26 results with modest revenue growth, improved margins, and a $339M share repurchase.
Ticker impact
Q3 FY26 revenue $1.066B, adjusted EPS $1.15 and $339.1M share repurchase disclosed.
Potential short‑term upside as investors price in strong cash flow and buyback capacity.
The numbers exceed consensus and the buyback adds support, likely prompting buying pressure.
Market effects
Positive signal for medical‑device sector, especially fertility and vision segments.
U.S. investors may favor COO; Asia‑Pacific vision segment weakness noted.
Highlights demand trends in fertility devices globally.
Counterpoint
CooperVision weakness and inventory reductions could pressure the stock despite the buyback.
Key entities
- companyCooper Companies Inc.
Medical‑device maker with fertility and vision segments.
